Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In this Centre for Tropical Medicine & Global Health (Nuffield Department of Medicine) blog, Rima Shretta (Honorary Visiting Research Fellow) outlines the direct and indirect costs of the COVID-19 pandemic which may impact the global economy.

Summary of the breakdown of the direct and indirect costs of COVID-19, adapted from Evans D, Over M. 2020. The Economic Impact of COVID-19 in low and middle-income countries. Center for Global Development, March 12, 2020: Washington, DC

The novel coronavirus that emerged in Wuhan, China, in December 2019 has leaped across borders, sending ripples around an interdependent and highly mobile global population. The virus, referred to as SARS-CoV-2, causes a disease that has been officially named COVID-19. On March 11, 2020, the Director General of the World Health Organization (WHO) declared COVID-19 a global pandemic. China has since managed to contain the virus through the use of draconian measures. However, Western Europe continues to grapple with severe outbreaks, while as of 6 April 2020 the United States (US) has over 330,000 cases, more than any other country. In New York City, the hardest hit state in the US, hospitals are barely coping with the soaring numbers of patients as supplies of personal protective equipment (PPE), ventilators and other essential equipment needed to treat patients are in short supply. On April 6, there were 1,275,856 confirmed cases and almost 70,000 deaths due to COVID-19 in 183 countries or regions globally. Given that testing rates have been poor in many countries, the true number of cases is likely to be much higher. As the virus continues to make its way around the world, the potential health impact of the pandemic in low-income countries, particularly in Africa, that already face struggling health care systems and a scarcity of skilled health workers, is of grave concern. While the pathogen’s epidemiological trajectory remains uncertain; various mathematical modelers have attempted to estimate the potential health impact of the disease. Their estimates range from 20% to 80% of the global population being infected.

There are currently no commercially available pharmaceutical interventions or vaccines to prevent infection, treat the disease or curb the pandemic. Countries are relying on behaviour change and non-pharmaceutical interventions, including, amongst others, self-isolation of symptomatic individuals; increased hand hygiene; physical distancing; working from home where possible; and school and business closure. National and local governments have closed their borders, restricting the movement of people in an attempt to contain the spread of the disease and to flatten the peak of the epidemic, with the aim of reducing the daily demand on health care resources. In the US, citizens of 40 states, along with a number of cities and counties, have been advised to stay home, while on 24 March, 1.3 billion people in India were placed under a nationwide ‘lockdown’ for 21 days.

Read the full blog on the Centre for Tropical Medicine & Global Health website

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

Medical Sciences Division receives REF 2021 results

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021. REF is the UK-wide assessment of research in universities, and provides an expert evaluation of the quality of the research outputs, impact and environment at subject level in each university.